Genmab


Strong Q3; guidance upgrade driven by FX

08/11/19 -"Darzalex continued to gain market share in Q3, while Arzerra was once again a disappointment. Given the favourable development in FX, the revenue guidance was upgraded by DKK300m and, as operating ..."

Pages
42
Language
English
Published on
08/11/19
You may also be interested by these reports :
18/11/19
The growth momentum in two (Healthcare and Life Science) out of the three divisions accelerated in Q3 and this is expected to continue (in Life ...

14/11/19
Merck’s profitability was materially driven by Healthcare, which generated strong organic growth and the profitability line was additionally helped ...

12/11/19
We have not heard a lot from Lonza in 2019, but the second CEO ‘disposal’ within a ten-month period looks quite strange to us. This is very atypical ...

11/11/19
Since we last pushed Novartis’ (ADD, Switzerland) investment story – “Novartis’ rejuvenation lacks speed” – in January 2018, the stock did well, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO